August 8, 2023 – Capstone Health Alliance and Bright Path Laboratories have entered into an agreement to collaborate to address current, and future, drug shortages for Capstone Health Alliance and their members including more than 245 hospitals representing over 120 health systems in 24 states and over 30,000 non-acute healthcare members nationwide to assure continuity of patient care and US production of important medicines. Bright Path and Capstone have identified key drug shortages impacting Capstone’s members for which Bright Path will develop and produce APIs for use in the final products.
“Capstone Health Alliance continues to address the drug shortage issues that continue to affect our member organizations and ultimately, their ability to provide optimal patient care” stated Capstone’s Director of Pharmacy Services, Fred J. Pane, R. Ph., FASHP, FABC. “Our commitment is to develop a consistent drug supply chain, while assuring the quality and integrity of this supply chain for our members. This innovative, disruptive, and collaborative initiative with Bright Path Labs, will enable Capstone Health Alliance members to obtain drugs, which are 100% U.S. manufactured using green technology. These drugs will also be supplied in dosage forms, better serving our member’s operational, financial, and clinical needs, all while decreasing their carbon footprint.”
“The necessity to embrace innovative pharmaceutical manufacturing in the United States has never been greater. Bright Path’s state of the art continuous flow advanced manufacturing platform will be an integral part of our nation’s supply chain readiness initiative,” said Tony Quinones, Founder and Chief Executive Officer of Bright Path Laboratories. “Through our collaboration with Capstone Health Alliance we’ll expand domestic reach in providing safe and cost-efficient drugs and continue our work in solving the immediate and long-term challenges in our medicinal supply chain through our transformative technology.